Breast cancer
Conditions
Interventions
Liposomal doxorubicin group:None
Epirubicin group:None
Sponsors
The Fifth Affiliated hospital of Sun Yet-sen University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years. 2. Female. 3. Pathologically confirmed breast cancer. 4. Undergoing chemotherapy at the Fifth Affiliated Hospital of Sun Yat-sen University between January 1, 2022 and March 31, 2025. 5. Chemotherapy regimen includes at least one cycle of liposomal doxorubicin or epirubicin. 6. Complete medical records, including demographic information, tumor staging, chemotherapy details, lab test results (blood tests before and after chemo), imaging reports (chest CT/X-ray), and infection-related diagnosis records.
Exclusion criteria
Exclusion criteria: 1.Definite diagnosis of infectious pneumonia within 2 weeks prior to the initiation of chemotherapy; 2.Comorbidity with active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.); 3.Concurrent use of other immunosuppressive agents (e.g., calcineurin inhibitors, anti-TNF agents, etc.) during or prior to chemotherapy, excluding glucocorticoids used for antiemetic therapy of chemotherapy-induced nausea and vomiting; 4.Comorbidity with human immunodeficiency virus (HIV) infection, active tuberculosis, or other chronic infectious diseases; 5.Incomplete medical records with missing key data (e.g., chemotherapy regimen, diagnostic basis for pneumonia, laboratory indicators) that preclude completion of the study analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of infectious pneumonia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Main pathogen types;composition of pneumonia etiologies;Risk factors; | — |
Countries
China
Contacts
Public ContactPeijian Peng
The Fifth Affiliated hospital of Sun Yet-sen University
Outcome results
None listed